Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio
Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT)...
NASDAQ: PNT
BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...
Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition
The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer...
Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio
Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma...